KNTPF (Kintor Pharmaceutical) ROC (Joel Greenblatt) %: -149.46% (As of Dec. 2025)


KNTPF Kintor Pharmaceutical Ltd KNTPF
26 GF Score
Price $0.25
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical ROC (Joel Greenblatt) %?

Kintor Pharmaceutical KNTPF 26 ROC (Joel Greenblatt) % is -149.46% as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 1,319 Biotechnology companies, Kintor Pharmaceutical ranks better than 59.44% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Kintor Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -149.46%.

The historical rank and industry rank for Kintor Pharmaceutical's ROC (Joel Greenblatt) % or its related term are showing as below:

KNTPF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -347.72   Med: -247.48   Max: -80.82
Current: -124.68

During the past 8 years, Kintor Pharmaceutical's highest ROC (Joel Greenblatt) % was -80.82%. The lowest was -347.72%. And the median was -247.48%.

KNTPF's ROC (Joel Greenblatt) % is ranked better than
59.44% of 1319 companies
in the Biotechnology industry
Industry Median: -291.86 vs KNTPF: -124.68

Kintor Pharmaceutical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 20.30% per year.


Kintor Pharmaceutical  (OTCPK:KNTPF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Kintor Pharmaceutical ROC (Joel Greenblatt) % Related Terms


Kintor Pharmaceutical ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical ROC (Joel Greenblatt) % Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -251.71 -156.56 -242.26 -81.03 -128.24

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -378.33 -68.81 -89.09 -97.98 -149.46

KNTPF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Kintor Pharmaceutical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintor Pharmaceutical ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's ROC (Joel Greenblatt) % falls into.


KNTPF
26GF Score
Kintor Pharmaceutical Ltd KNTPF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.418 + 0.06) - (7.735 + 0 + 0)
=-7.257

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.397 + 1.717 + 0.448) - (5.959 + 0 + 3.5527136788005E-15)
=-3.397

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Kintor Pharmaceutical for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-33.424/( ( (23.446 + max(-7.257, 0)) + (21.281 + max(-3.397, 0)) )/ 2 )
=-33.424/( ( 23.446 + 21.281 )/ 2 )
=-33.424/22.3635
=-149.46 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -149.46% mean?
Kintor Pharmaceutical (KNTPF) has a ROC (Joel Greenblatt) % of -149.46% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kintor Pharmaceutical and its competitors. According to the industry distribution chart, Kintor Pharmaceutical ranks #535 out of 1319 companies in the Biotechnology industry, placing it in the top 40.6%.
Is Kintor Pharmaceutical's ROC (Joel Greenblatt) % too high?
Kintor Pharmaceutical's current ROC (Joel Greenblatt) % is -149.46%. Based on the distribution chart, Kintor Pharmaceutical ranks #535 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kintor Pharmaceutical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #535 out of 1319 companies for ROC (Joel Greenblatt) %. This puts Kintor Pharmaceutical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current ROC (Joel Greenblatt) % is -149.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current ROC (Joel Greenblatt) % of -149.46%. The current ROC (Joel Greenblatt) % is -149.46%. Kintor Pharmaceutical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current ROC (Joel Greenblatt) % is -149.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
26GF Score

Get the complete analysis for KNTPF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price